Tissue Regenix Group Stock Current Valuation
| TRX Stock | 58.50 1.50 2.50% |
Valuation analysis of Tissue Regenix Group helps investors to measure Tissue Regenix's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. At present, Tissue Regenix's Begin Period Cash Flow is projected to decrease significantly based on the last few years of reporting. The current year's Total Cash From Operating Activities is expected to grow to about 982.8 K, whereas Cash And Short Term Investments are forecasted to decline to about 4 M. Fundamental drivers impacting Tissue Regenix's valuation include:
Price Book 1.7173 | Enterprise Value 47.3 M | Enterprise Value Ebitda 47.5625 | Price Sales 1.3106 | Forward PE 112.3596 |
Overvalued
Today
Please note that Tissue Regenix's price fluctuation is very steady at this time. Calculation of the real value of Tissue Regenix Group is based on 3 months time horizon. Increasing Tissue Regenix's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Tissue stock is determined by what a typical buyer is willing to pay for full or partial control of Tissue Regenix Group. Since Tissue Regenix is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Tissue Stock. However, Tissue Regenix's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 58.5 | Real 48.72 | Hype 58.49 | Naive 56.16 |
The real value of Tissue Stock, also known as its intrinsic value, is the underlying worth of Tissue Regenix Group Company, which is reflected in its stock price. It is based on Tissue Regenix's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Tissue Regenix's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Tissue Regenix Group helps investors to forecast how Tissue stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Tissue Regenix more accurately as focusing exclusively on Tissue Regenix's fundamentals will not take into account other important factors: Tissue Regenix Group Company Current Valuation Analysis
Tissue Regenix's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Tissue Regenix Current Valuation | 47.34 M |
Most of Tissue Regenix's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Tissue Regenix Group is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Tissue Regenix Group has a Current Valuation of 47.34 M. This is much higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The current valuation for all United Kingdom stocks is notably lower than that of the firm.
Tissue Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Tissue Regenix's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Tissue Regenix could also be used in its relative valuation, which is a method of valuing Tissue Regenix by comparing valuation metrics of similar companies.Tissue Regenix is currently under evaluation in current valuation category among its peers.
Tissue Fundamentals
| Return On Equity | -0.0331 | ||||
| Return On Asset | 0.005 | ||||
| Profit Margin | (0.03) % | ||||
| Operating Margin | 0.03 % | ||||
| Current Valuation | 47.34 M | ||||
| Shares Outstanding | 71.23 M | ||||
| Shares Owned By Insiders | 51.91 % | ||||
| Shares Owned By Institutions | 34.85 % | ||||
| Price To Book | 1.72 X | ||||
| Price To Sales | 1.31 X | ||||
| Revenue | 29.49 M | ||||
| Gross Profit | 11.26 M | ||||
| EBITDA | 446 K | ||||
| Net Income | (1.67 M) | ||||
| Total Debt | 9.39 M | ||||
| Book Value Per Share | 0.43 X | ||||
| Cash Flow From Operations | 1.04 M | ||||
| Earnings Per Share | (0.01) X | ||||
| Target Price | 120.0 | ||||
| Number Of Employees | 82 | ||||
| Beta | 1.58 | ||||
| Market Capitalization | 41.67 M | ||||
| Total Asset | 43.24 M | ||||
| Retained Earnings | (123.76 M) | ||||
| Working Capital | 14.36 M | ||||
| Net Asset | 43.24 M |
About Tissue Regenix Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Tissue Regenix Group's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Tissue Regenix using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Tissue Regenix Group based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| BTC | Bitcoin | |
| TRX | TRON | |
| BNB | Binance Coin |
Other Information on Investing in Tissue Stock
Tissue Regenix financial ratios help investors to determine whether Tissue Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Tissue with respect to the benefits of owning Tissue Regenix security.